JP2017515470A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017515470A5 JP2017515470A5 JP2016565168A JP2016565168A JP2017515470A5 JP 2017515470 A5 JP2017515470 A5 JP 2017515470A5 JP 2016565168 A JP2016565168 A JP 2016565168A JP 2016565168 A JP2016565168 A JP 2016565168A JP 2017515470 A5 JP2017515470 A5 JP 2017515470A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- seq
- antibody fragment
- sequence
- domain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 19
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 19
- 108020004707 nucleic acids Proteins 0.000 claims 8
- 150000007523 nucleic acids Chemical class 0.000 claims 8
- 102000039446 nucleic acids Human genes 0.000 claims 8
- 239000003814 drug Substances 0.000 claims 6
- 239000002773 nucleotide Substances 0.000 claims 6
- 125000003729 nucleotide group Chemical group 0.000 claims 6
- 210000003719 b-lymphocyte Anatomy 0.000 claims 5
- 239000000611 antibody drug conjugate Substances 0.000 claims 4
- 229940049595 antibody-drug conjugate Drugs 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 208000035475 disorder Diseases 0.000 claims 4
- 230000001717 pathogenic effect Effects 0.000 claims 4
- 210000004027 cell Anatomy 0.000 claims 3
- 210000004180 plasmocyte Anatomy 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- 210000001806 memory b lymphocyte Anatomy 0.000 claims 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 208000037914 B-cell disorder Diseases 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 208000007452 Plasmacytoma Diseases 0.000 claims 1
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 claims 1
- 238000007792 addition Methods 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 230000001580 bacterial effect Effects 0.000 claims 1
- 230000000295 complement effect Effects 0.000 claims 1
- 230000037430 deletion Effects 0.000 claims 1
- 238000012217 deletion Methods 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000002068 genetic effect Effects 0.000 claims 1
- 150000004676 glycans Chemical class 0.000 claims 1
- 210000004408 hybridoma Anatomy 0.000 claims 1
- 208000026278 immune system disease Diseases 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 238000003780 insertion Methods 0.000 claims 1
- 230000037431 insertion Effects 0.000 claims 1
- 230000003993 interaction Effects 0.000 claims 1
- 210000004962 mammalian cell Anatomy 0.000 claims 1
- 150000002482 oligosaccharides Polymers 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 208000031223 plasma cell leukemia Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 230000005945 translocation Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14166729.5 | 2014-04-30 | ||
| EP14166729 | 2014-04-30 | ||
| PCT/EP2015/059562 WO2015166073A1 (en) | 2014-04-30 | 2015-04-30 | Humanized antibodies against cd269 (bcma) |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020142486A Division JP7189913B2 (ja) | 2014-04-30 | 2020-08-26 | Ｃｄ２６９（ｂｃｍａ）に対するヒト化抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017515470A JP2017515470A (ja) | 2017-06-15 |
| JP2017515470A5 true JP2017515470A5 (enExample) | 2018-06-07 |
| JP6755805B2 JP6755805B2 (ja) | 2020-09-16 |
Family
ID=50677985
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016565168A Active JP6755805B2 (ja) | 2014-04-30 | 2015-04-30 | Ｃｄ２６９（ｂｃｍａ）に対するヒト化抗体 |
| JP2020142486A Active JP7189913B2 (ja) | 2014-04-30 | 2020-08-26 | Ｃｄ２６９（ｂｃｍａ）に対するヒト化抗体 |
| JP2022194533A Pending JP2023025202A (ja) | 2014-04-30 | 2022-12-05 | Ｃｄ２６９（ｂｃｍａ）に対するヒト化抗体 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020142486A Active JP7189913B2 (ja) | 2014-04-30 | 2020-08-26 | Ｃｄ２６９（ｂｃｍａ）に対するヒト化抗体 |
| JP2022194533A Pending JP2023025202A (ja) | 2014-04-30 | 2022-12-05 | Ｃｄ２６９（ｂｃｍａ）に対するヒト化抗体 |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US10144782B2 (enExample) |
| EP (1) | EP3137500A1 (enExample) |
| JP (3) | JP6755805B2 (enExample) |
| KR (3) | KR102526945B1 (enExample) |
| CN (2) | CN106661109B (enExample) |
| AU (1) | AU2015254526B2 (enExample) |
| BR (1) | BR112016024546A2 (enExample) |
| CA (1) | CA2944962A1 (enExample) |
| IL (2) | IL248257B2 (enExample) |
| MX (2) | MX375800B (enExample) |
| NZ (1) | NZ725701A (enExample) |
| RU (2) | RU2749041C2 (enExample) |
| SG (1) | SG11201608415QA (enExample) |
| UA (1) | UA121031C2 (enExample) |
| WO (1) | WO2015166073A1 (enExample) |
| ZA (1) | ZA201607018B (enExample) |
Families Citing this family (80)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2914628A1 (en) | 2012-11-01 | 2015-09-09 | Max-Delbrück-Centrum für Molekulare Medizin | An antibody that binds cd269 (bcma) suitable for use in the treatment of plasma cell diseases such as multiple myeloma and autoimmune diseases |
| WO2014124280A1 (en) | 2013-02-08 | 2014-08-14 | Institute For Myeloma & Bone Cancer Research | Improved diagnostic, prognostic, and monitoring methods for multiple myeloma, chronic lymphocytic leukemia, and b-cell non-hodgkin lymphoma |
| KR102526945B1 (ko) * | 2014-04-30 | 2023-04-27 | 막스-델부뤽-센트럼 퓌어 몰레쿨라레 메디친 인 데어 헬름홀츠-게마인샤프트 | Ｃｄ269에 대한 인간화 항체 |
| WO2016014565A2 (en) | 2014-07-21 | 2016-01-28 | Novartis Ag | Treatment of cancer using humanized anti-bcma chimeric antigen receptor |
| JP6921001B2 (ja) | 2015-04-13 | 2021-08-18 | ファイザー・インク | Ｂ細胞成熟抗原を標的にするキメラ抗原受容体 |
| ES3012402T3 (en) | 2015-04-13 | 2025-04-09 | Pfizer | Therapeutic antibodies and their uses |
| US11698369B2 (en) | 2016-01-12 | 2023-07-11 | Oncotracker, Inc. | Methods for monitoring immune status of a subject |
| IL311107A (en) * | 2016-02-17 | 2024-04-01 | Seagen Inc | BCMA antibodies and their use for the treatment of cancer and immune disorders |
| US12048718B2 (en) * | 2016-06-07 | 2024-07-30 | Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Geminschaft | Chimeric antigen receptor and CAR-T cells that bind BCMA |
| EA201891851A1 (ru) * | 2016-09-16 | 2019-04-30 | Сиэтл Дженетикс, Инк. | Антитела против bcma и их применение для лечения злокачественных новообразований и иммунологических нарушений |
| PT3558390T (pt) * | 2016-12-23 | 2024-10-29 | Heidelberg Pharma Res Gmbh | Conjugados amanitina anticorpo |
| CN108285489A (zh) * | 2017-01-09 | 2018-07-17 | 上海恒润达生生物科技有限公司 | 靶向BCMA-BBz-tEGFR的嵌合抗原受体及其用途 |
| WO2018144535A1 (en) | 2017-01-31 | 2018-08-09 | Novartis Ag | Treatment of cancer using chimeric t cell receptor proteins having multiple specificities |
| CN108395478A (zh) * | 2017-02-04 | 2018-08-14 | 上海恒润达生生物科技有限公司 | 靶向bcma的嵌合抗原受体并对其双重修饰的方法及其用途 |
| SG11201907580SA (en) | 2017-02-17 | 2019-09-27 | Hutchinson Fred Cancer Res | Combination therapies for treatment of bcma-related cancers and autoimmune disorders |
| EP3615055A1 (en) | 2017-04-28 | 2020-03-04 | Novartis AG | Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor |
| WO2018201051A1 (en) | 2017-04-28 | 2018-11-01 | Novartis Ag | Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor |
| US11635435B2 (en) | 2017-06-13 | 2023-04-25 | Oncotracker, Inc. | Diagnostic, prognostic, and monitoring methods for solid tumor cancers |
| WO2019035938A1 (en) | 2017-08-16 | 2019-02-21 | Elstar Therapeutics, Inc. | MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF |
| BR112020007576A2 (pt) | 2017-10-18 | 2020-09-24 | Novartis Ag | composições e métodos para degradação de proteína seletiva |
| US20200360431A1 (en) | 2017-11-15 | 2020-11-19 | Novartis Ag | Bcma-targeting chimeric antigen receptor, cd19-targeting chimeric antigen receptor, and combination therapies |
| TW201925782A (zh) | 2017-11-30 | 2019-07-01 | 瑞士商諾華公司 | 靶向bcma之嵌合抗原受體及其用途 |
| TW201930591A (zh) | 2018-01-08 | 2019-08-01 | 瑞士商諾華公司 | 用於與嵌合抗原受體療法併用之免疫增強rna |
| EP3737692A4 (en) | 2018-01-09 | 2021-09-29 | Elstar Therapeutics, Inc. | CALRETICULIN AND MODIFIED T-LYMPHOCYTES BINDING CONSTRUCTIONS FOR THE TREATMENT OF DISEASES |
| CA3090249A1 (en) | 2018-01-31 | 2019-08-08 | Novartis Ag | Combination therapy using a chimeric antigen receptor |
| JP7438953B2 (ja) * | 2018-02-01 | 2024-02-27 | イノベント バイオロジックス （スウツォウ） カンパニー，リミテッド | 完全ヒト化抗ｂ細胞成熟抗原（ｂｃｍａ）の単鎖抗体およびその応用 |
| WO2019160956A1 (en) | 2018-02-13 | 2019-08-22 | Novartis Ag | Chimeric antigen receptor therapy in combination with il-15r and il15 |
| MX2020008718A (es) * | 2018-02-21 | 2020-12-07 | Celgene Corp | Anticuerpos de union a bcma y usos de los mismos. |
| US12152073B2 (en) | 2018-03-14 | 2024-11-26 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to calreticulin and uses thereof |
| TWI848951B (zh) | 2018-06-01 | 2024-07-21 | 瑞士商諾華公司 | 針對ｂｃｍａ之結合分子及其用途 |
| AU2019284911A1 (en) | 2018-06-13 | 2020-12-17 | Novartis Ag | BCMA chimeric antigen receptors and uses thereof |
| CN112105391B (zh) * | 2018-06-26 | 2024-05-14 | 爱必乐生物公司 | 抗-bcma抗体及其用途 |
| AU2019297451A1 (en) | 2018-07-03 | 2021-01-28 | Marengo Therapeutics, Inc. | Anti-TCR antibody molecules and uses thereof |
| TWI838389B (zh) | 2018-07-19 | 2024-04-11 | 美商再生元醫藥公司 | 雙特異性抗-BCMAｘ抗-CD3抗體及其用途 |
| MD3823665T2 (ro) | 2018-07-19 | 2024-05-31 | Regeneron Pharma | Receptori antigenci chimerici cu specificitate BCMA și utilizările acestora |
| ES3042082T3 (en) | 2018-08-31 | 2025-11-18 | Novartis Ag | Methods of making chimeric antigen receptor-expressing cells |
| WO2020047449A2 (en) | 2018-08-31 | 2020-03-05 | Novartis Ag | Methods of making chimeric antigen receptor-expressing cells |
| PT3749338T (pt) | 2019-01-16 | 2024-09-20 | Caribou Biosciences Inc | Anticorpo de bcma humanizado e células bcma-car-t |
| EP3927747A1 (en) | 2019-02-21 | 2021-12-29 | Marengo Therapeutics, Inc. | Antibody molecules that bind to nkp30 and uses thereof |
| CN119661722A (zh) | 2019-02-21 | 2025-03-21 | 马伦戈治疗公司 | 结合t细胞相关癌细胞的多功能分子及其用途 |
| KR20210134339A (ko) | 2019-02-25 | 2021-11-09 | 노파르티스 아게 | 바이러스 전달을 위한 메조다공성 실리카 입자 조성물 |
| WO2020191316A1 (en) | 2019-03-21 | 2020-09-24 | Novartis Ag | Car-t cell therapies with enhanced efficacy |
| WO2020210678A1 (en) | 2019-04-12 | 2020-10-15 | Novartis Ag | Methods of making chimeric antigen receptor-expressing cells |
| US20220251152A1 (en) | 2019-04-24 | 2022-08-11 | Novartis Ag | Compositions and methods for selective protein degradation |
| MX2021013391A (es) * | 2019-05-03 | 2022-01-26 | Celgene Corp | Conjugado de anticuerpo anti-bcma, composiciones que comprenden el mismo, y metodos de fabricacion y uso del mismo. |
| BR112021023048A2 (pt) | 2019-05-21 | 2022-04-19 | Novartis Ag | Moléculas de ligação a cd19 e usos das mesmas |
| BR112022001546A2 (pt) * | 2019-07-30 | 2022-03-22 | Jiangsu Hansoh Pharmaceutical Group Co Ltd | Anticorpo anti-bcma, fragmento de ligação ao antígeno do mesmo e uso médico do mesmo |
| HRP20240037T1 (hr) * | 2019-08-02 | 2024-03-29 | Fundació de Recerca Clínic Barcelona-Institut d'Investigacions Biomèdiques August Pi i Sunyer (FRCB-IDIBAPS) | Car t-stanice prema bcma za liječenje multiplog mijeloma |
| CN114867846A (zh) * | 2019-09-25 | 2022-08-05 | 菲特治疗公司 | 多靶向效应细胞和其用途 |
| US12479922B2 (en) | 2019-10-10 | 2025-11-25 | Cytolynx Therapeutics Hong Kong Limited | Humanized monoclonal antibody targeting BCMA and having human monkey cross-reactivity |
| CA3163104A1 (en) | 2019-11-26 | 2021-06-03 | Novartis Ag | Chimeric antigen receptors and uses thereof |
| BR112022011964A2 (pt) * | 2019-12-17 | 2022-09-06 | Shenzhen Feipeng Biological Therapy Co Ltd | Anticorpo de ligação a bcma e uso do mesmo |
| GB2609554B (en) | 2020-01-03 | 2025-08-20 | Marengo Therapeutics Inc | Anti-TCR antibody molecules and uses thereof |
| US20230256017A1 (en) | 2020-02-27 | 2023-08-17 | Jennifer Brogdon | Methods of making chimeric antigen receptor-expressing cells |
| BR112022016633A2 (pt) | 2020-02-27 | 2022-12-13 | Novartis Ag | Métodos para produzir células que expressam receptor de antígeno quimérico |
| CN113637073B (zh) * | 2020-05-11 | 2024-04-12 | 上海赛比曼生物科技有限公司 | Bcma抗体及其制备和应用 |
| CN116096752B (zh) | 2020-06-05 | 2025-10-28 | 卫材R&D管理有限公司 | 抗bcma抗体-药物缀合物及其使用方法 |
| US20230332104A1 (en) | 2020-06-11 | 2023-10-19 | Novartis Ag | Zbtb32 inhibitors and uses thereof |
| US20230302155A1 (en) | 2020-08-21 | 2023-09-28 | Novartis Ag | Compositions and methods for in vivo generation of car expressing cells |
| CA3187272A1 (en) | 2020-10-08 | 2022-04-14 | Thorsten Ross | Trispecific binders |
| WO2022094245A1 (en) | 2020-10-30 | 2022-05-05 | Vor Biopharma, Inc. | Compositions and methods for bcma modification |
| CN112614596B (zh) * | 2020-12-22 | 2023-01-10 | 厦门承葛生物科技有限公司 | 一种肠道菌群移植治疗溃疡性结肠炎的供受体配型方法 |
| KR20240004462A (ko) | 2021-04-08 | 2024-01-11 | 마렝고 테라퓨틱스, 인크. | Tcr에 결합하는 다기능성 분자 및 이의 용도 |
| CN118056008A (zh) | 2021-04-27 | 2024-05-17 | 诺华股份有限公司 | 病毒载体生产系统 |
| US11931420B2 (en) | 2021-04-30 | 2024-03-19 | Celgene Corporation | Combination therapies using an anti-BCMA antibody drug conjugate (ADC) in combination with a gamma secretase inhibitor (GSI) |
| EP4376958A1 (en) | 2021-07-30 | 2024-06-05 | Affimed GmbH | Duplexbodies |
| EP4384544A1 (en) | 2021-08-11 | 2024-06-19 | Sana Biotechnology, Inc. | Genetically modified cells for allogeneic cell therapy |
| WO2023019225A2 (en) | 2021-08-11 | 2023-02-16 | Sana Biotechnology, Inc. | Genetically modified cells for allogeneic cell therapy to reduce instant blood mediated inflammatory reactions |
| EP4384598A1 (en) | 2021-08-11 | 2024-06-19 | Sana Biotechnology, Inc. | Genetically modified cells for allogeneic cell therapy to reduce complement-mediated inflammatory reactions |
| AU2022325232A1 (en) | 2021-08-11 | 2024-02-08 | Sana Biotechnology, Inc. | Genetically modified primary cells for allogeneic cell therapy |
| WO2023021477A1 (en) | 2021-08-20 | 2023-02-23 | Novartis Ag | Methods of making chimeric antigen receptor–expressing cells |
| TW202334221A (zh) | 2021-11-03 | 2023-09-01 | 德商安富美德有限公司 | 雙特異性cd16a結合劑 |
| KR20240155390A (ko) | 2022-02-17 | 2024-10-28 | 사나 바이오테크놀로지, 인크. | 조작된 cd47 단백질 및 이의 용도 |
| WO2023215725A1 (en) | 2022-05-02 | 2023-11-09 | Fred Hutchinson Cancer Center | Compositions and methods for cellular immunotherapy |
| WO2024089639A1 (en) | 2022-10-26 | 2024-05-02 | Novartis Ag | Lentiviral formulations |
| WO2024097313A1 (en) | 2022-11-02 | 2024-05-10 | Sana Biotechnology, Inc. | Methods for producing t cell therapy products |
| WO2024197157A1 (en) | 2023-03-21 | 2024-09-26 | Biograph 55, Inc. | Cd19/cd38 multispecific antibodies |
| WO2025043172A1 (en) | 2023-08-23 | 2025-02-27 | Sana Biotechnology, Inc. | Modified cd47 proteins and their uses |
| WO2025101820A1 (en) | 2023-11-08 | 2025-05-15 | Fred Hutchinson Cancer Center | Compositions and methods for cellular immunotherapy |
| WO2025217258A1 (en) * | 2024-04-09 | 2025-10-16 | The Rockefeller University | Nptx1 antibodies |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002066516A2 (en) | 2001-02-20 | 2002-08-29 | Zymogenetics, Inc. | Antibodies that bind both bcma and taci |
| AR039067A1 (es) * | 2001-11-09 | 2005-02-09 | Pfizer Prod Inc | Anticuerpos para cd40 |
| US8420353B2 (en) | 2002-03-22 | 2013-04-16 | Aprogen, Inc. | Humanized antibody and process for preparing same |
| ATE485057T1 (de) * | 2005-05-26 | 2010-11-15 | Seattle Genetics Inc | Humanisierte antikörper gegen cd40 und verfahren zu ihrer anwendung |
| US9382327B2 (en) * | 2006-10-10 | 2016-07-05 | Vaccinex, Inc. | Anti-CD20 antibodies and methods of use |
| WO2009070767A2 (en) * | 2007-11-28 | 2009-06-04 | Whitehead Institute For Biomedical Research | Systemic instigation systems to study tumor growth or metastasis |
| US20110158995A1 (en) * | 2008-07-28 | 2011-06-30 | Renault S.A.S | Multi-Specific Binding Proteins Targeting B Cell Disorders |
| HRP20161194T1 (hr) * | 2009-03-10 | 2016-11-04 | Biogen Ma Inc. | Anti-bcma protutijela |
| MX2011010158A (es) | 2009-04-07 | 2011-10-17 | Roche Glycart Ag | Anticuerpos biespecificos anti-erbb-2/anti-c-met. |
| EP2640750A1 (en) * | 2010-11-16 | 2013-09-25 | Boehringer Ingelheim International GmbH | Agents and methods for treating diseases that correlate with bcma expression |
| US20130101599A1 (en) | 2011-04-21 | 2013-04-25 | Boehringer Ingelheim International Gmbh | Bcma-based stratification and therapy for multiple myeloma patients |
| PH12013502421A1 (en) * | 2011-05-27 | 2014-01-06 | Glaxo Group Ltd | Bcma (cd269/tnfrsf17) -binding proteins |
| EP2914628A1 (en) * | 2012-11-01 | 2015-09-09 | Max-Delbrück-Centrum für Molekulare Medizin | An antibody that binds cd269 (bcma) suitable for use in the treatment of plasma cell diseases such as multiple myeloma and autoimmune diseases |
| KR102526945B1 (ko) * | 2014-04-30 | 2023-04-27 | 막스-델부뤽-센트럼 퓌어 몰레쿨라레 메디친 인 데어 헬름홀츠-게마인샤프트 | Ｃｄ269에 대한 인간화 항체 |
-
2015
- 2015-04-30 KR KR1020227018383A patent/KR102526945B1/ko active Active
- 2015-04-30 CN CN201580021693.5A patent/CN106661109B/zh active Active
- 2015-04-30 KR KR1020237013978A patent/KR102632731B1/ko active Active
- 2015-04-30 SG SG11201608415QA patent/SG11201608415QA/en unknown
- 2015-04-30 UA UAA201612087A patent/UA121031C2/uk unknown
- 2015-04-30 JP JP2016565168A patent/JP6755805B2/ja active Active
- 2015-04-30 WO PCT/EP2015/059562 patent/WO2015166073A1/en not_active Ceased
- 2015-04-30 AU AU2015254526A patent/AU2015254526B2/en active Active
- 2015-04-30 US US15/306,438 patent/US10144782B2/en active Active
- 2015-04-30 RU RU2016146486A patent/RU2749041C2/ru active
- 2015-04-30 EP EP15720954.5A patent/EP3137500A1/en active Pending
- 2015-04-30 CN CN202110761923.9A patent/CN113491776B/zh active Active
- 2015-04-30 KR KR1020167033409A patent/KR102405492B1/ko active Active
- 2015-04-30 IL IL248257A patent/IL248257B2/en unknown
- 2015-04-30 NZ NZ725701A patent/NZ725701A/en unknown
- 2015-04-30 BR BR112016024546-6A patent/BR112016024546A2/pt not_active Application Discontinuation
- 2015-04-30 CA CA2944962A patent/CA2944962A1/en active Pending
- 2015-04-30 IL IL303667A patent/IL303667A/en unknown
- 2015-04-30 MX MX2016013767A patent/MX375800B/es active IP Right Grant
- 2015-04-30 RU RU2021115081A patent/RU2021115081A/ru unknown
-
2016
- 2016-10-12 ZA ZA2016/07018A patent/ZA201607018B/en unknown
- 2016-10-20 MX MX2020010530A patent/MX2020010530A/es unknown
-
2018
- 2018-10-25 US US16/170,575 patent/US10851172B2/en active Active
-
2020
- 2020-08-26 JP JP2020142486A patent/JP7189913B2/ja active Active
- 2020-10-23 US US17/079,075 patent/US11820829B2/en active Active
-
2022
- 2022-12-05 JP JP2022194533A patent/JP2023025202A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017515470A5 (enExample) | ||
| RU2016146486A (ru) | Гуманизированные антитела против cd269 (bcma) | |
| JP2023025202A5 (enExample) | ||
| Tisa et al. | Quadrivalent influenza vaccine: a new opportunity to reduce the influenza burden | |
| JP2015535002A5 (enExample) | ||
| JP2018064580A5 (enExample) | ||
| JP2010166916A5 (enExample) | ||
| RU2018137842A (ru) | Агонисты рецепторов глюкагона/glp-1 для лечения ожирения | |
| RU2016101711A (ru) | Высокостабильный т-клеточный рецептор и способ его получения и применения | |
| RU2021133819A (ru) | Анти-lag-3 антитела | |
| JP2008508859A5 (enExample) | ||
| JP2012510461A5 (enExample) | ||
| ME00519B (me) | Antitijela visokog afiniteta prema humanom il-6 receptoru | |
| NZ607394A (en) | Vegf-binding molecules | |
| JP2016538830A5 (enExample) | ||
| JP2011514150A5 (enExample) | ||
| JP2013502204A5 (enExample) | ||
| JP2016513467A5 (enExample) | ||
| HRP20150799T1 (hr) | Sastavi i postupci za protutijela protiv komplementnog proteina c5 | |
| JP2016026215A5 (enExample) | ||
| HK1224229A1 (zh) | 取代的核苷，核苷酸及其类似物 | |
| JP2016512425A5 (enExample) | ||
| NZ600348A (en) | Anti-c5a binding moieties with high blocking activity | |
| JP2015533490A5 (enExample) | ||
| HRP20161740T1 (hr) | Ljudske molekule za vezanje koje su sposobne neutralizirati viruse influence a filogenetske skupine 1 i filogenetske skupine 2, te viruse influence b |